Ivabradine in Heart Failure Patients with Reduced Ejection Fraction and History of Paroxysmal Atrial Fibrillation
Open Access
- 12 May 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 9 (4) , 2548-2557
Abstract
Aims: Ivabradine is indicated for heart failure (HF) patients with reduced ejection fraction (HFrEF), but limited data are available with regards to the use of ivabradine in those with a history of paroxysmal atrial fibrillation (AF). To assess the effect of ivabradine in HFrEF patients with paroxysmal AF, we analysed heart failure (HF) hospitalization and mortality from multiple-centre registry database. Methods and results: We conducted a multicentre observational matched cohort study, and this study enrolled patient with symptomatic HFrEF from 1 January 2015 to 31 December 2018 who had a history of paroxysmal AF in Chang Gung Memorial Hospital medical database in Taiwan. A total of 2042 patients were eligible for the study, of whom 887 were prescribed with ivabradine and 1115 were not. The primary outcome, including HF hospitalization and cardiovascular death, and individual outcome during the 12 month observation period were analysed after inverse probability of treatment weighting. The ivabradine group had significantly lower mean heart rate after 12 months follow-up than the non-ivabradine group (P < 0.05). The primary outcome was significantly higher in the ivabradine group than the non-ivabradine group after 12 months follow-up (hazard ratio [HR] = 1.58; 95% confidence interval [CI], 1.26–2.00, P < 0.001). Moreover, the ivabradine group had a significantly higher event rate of HF hospitalization (HR = 1.56; 95% CI, 1.40–1.75, P < 0.001) and HF death (HR = 1.67; 95% CI, 1.14–2.44, P = 0.009) than the non-ivabradine group. Conclusions: Ivabradine treatment was associated with an increased risk of HF hospitalization in symptomatic HFrEF patients with a history of paroxysmal AF. Further prospective randomized studies are warranted.Keywords
Funding Information
- Chang Gung Memorial Hospital, Taiwan (CMRPG6H0482)
- Chang Gung Memorial Hospital, Taiwan (CMRPG6H0481)
- Chang Gung Memorial Hospital, Taiwan (CGRPG6J0041)
This publication has 19 references indexed in Scilit:
- Emerging role of ivabradine for rate control in atrial fibrillationTherapeutic Advances in Cardiovascular Disease, 2016
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2016
- Addition of ivabradine to betablockers in patients with atrial fibrillation: Effects on heart rate and exercise toleranceInternational Journal of Cardiology, 2016
- Ivabradine for rate control in atrial fibrillationInternational Journal of Cardiology, 2015
- Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trialsHeart, 2014
- Novel insights into the distribution of cardiac HCN channels: An expression study in the mouse heartJournal of Molecular and Cellular Cardiology, 2011
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyThe Lancet, 2010
- Funny channels in the control of cardiac rhythm and mode of action of selective blockersPharmacological Research, 2006
- Survival Bias Associated with Time-to-Treatment Initiation in Drug Effectiveness Evaluation: A Comparison of MethodsAmerican Journal of Epidemiology, 2005
- Marginal Structural Models to Estimate the Causal Effect of Zidovudine on the Survival of HIV-Positive MenEpidemiology, 2000